Immunoglobulin (Ig)A is the most abundant immunoglobulin in humans, and in the airway mucosa secretory IgA (sIgA) plays a pivotal role in first-line defense against invading pathogens and antigens. IgA has been reported to also have pathogenic effects, including possible worsening of the prognosis of idiopathic pulmonary fibrosis (IPF). However, the precise effects of IgA on lung fibroblasts remain unclear, and we aimed to elucidate how IgA activates human lung fibroblasts. We found that sIgA, but not monomeric IgA (mIgA), induced interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1 and granulocyte-macrophage colonystimulating factor (GM-CSF) production by normal human lung fibroblasts (NHLFs) at both the protein and mRNA levels. sIgA also promoted proliferation of NHLFs and collagen gel contraction comparable to with transforming growth factor (TGF)-β, which is involved in fibrogenesis in IPF. Also, Western blot analysis and real-time quantitative polymerase chain reaction (PCR) revealed that sIgA enhanced production of α-smooth muscle actin (α-SMA) and collagen type I (Col I) by NHLFs. Flow cytometry showed that NHLFs bound sIgA, and among the known IgA receptors, NHLFs significantly expressed CD71 (transferrin receptor). Transfection of siRNA targeting CD71 partially but significantly suppressed cytokine production by NHLFs co-cultured with sIgA. Our findings suggest that sIgA may promote human lung inflammation and fibrosis by enhancing production of inflammatory or fibrogenic cytokines as well as extracellular matrix, inducing fibroblast differentiation into myofibroblasts and promoting human lung fibroblast proliferation. sIgA's enhancement of cytokine production may be due partially to its binding to CD71 or the secretory component.
Introduction
Immunoglobulin (Ig) A, produced at approximately 40-60 mg/kg of body weight/day, is the most abundant immunoglobulin in humans [1] . IgA-producing plasma cells reside mainly in mucosal tissues, such as in the respiratory, gastrointestinal and genitourinary tracts, sites that are directly exposed to the external environment. There, IgA comes into contact with pathogenic microorganisms as well as invading antigens and toxins and acts as the first line of defense [2] . In the blood, approximately 90% of IgA exists as monomeric IgA (mIgA) [3] . In contrast, approximately half of IgA in airway secretions is in the form of secretory IgA (sIgA). sIgA is a J chain-containing dimeric IgA (dIgA), with a secretory component (SC) that is conferred during the process between binding to polymeric immunoglobulin receptor on the basolateral surfaces of mucosal epithelial cells and release into the lumen [4] . sIgA entraps pathogens and antigens and serves to promote their clearance and removal through receptor blockade and immune exclusion. In addition, IgA has been shown to improve the viscoelastic properties of
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airway secretions, which would help mucocilliary transport [5] . Thus, IgA is commonly thought of as a key immunoglobulin for human immunity. In contrast to IgA's protective role in human immunity against infectious, allergic and autoimmune disorders, IgA has also been shown to have somewhat unfavorable effects in human biology. For example, sIgA is a known eosinophil and basophil activator in terms of enhancing degranulation, which may have a protective effect against helminth infections but an accelerating effect on hypersensitivity disorders such as asthma [6] [7] [8] . Similarly, aggregation of IgA induces activation of mesangial cells, which may be involved in initiation of the pathology of IgA nephropathy [9] . Therefore, IgA might be unfavorable to human immunity in certain disease conditions.
A recent report showed that the level of serum IgA can be used as a prognostic marker for idiopathic pulmonary fibrosis (IPF): a high level of serum IgA was associated with poor survival of IPF patients [10] . Because transforming growth factor (TGF)-β, the most potent cytokine involved in fibrogenesis in IPF, is critical for mucosal IgA responses [11] , it is conceivable that IgA might play an important role in the pathogenesis of IPF. Interactions between fibroblasts and alveolar epithelial cells appear to be the central mechanism in that pathogenesis [12, 13] . In particular, progressive accumulation of activated fibroblasts and differentiated myofibroblasts in response to TGF-β and deposition of extracellular matrix in the lung are observed in IPF [14] . The effects of IgA on lung fibroblasts and myofibroblasts have not been well elucidated, and the pathogenic role of IgA in fibrosing diseases such as IPF remains largely unclear. Here, we sought to elucidate the effects of IgA on activation of human lung fibroblasts.
Materials and methods

Reagents
Purified human sIgA was obtained from MP Biomedicals (Fountain Parkway, Solon, OH, USA) [8] , and mIgA from human serum was obtained from Oriental Yeast Co. (Tokyo, Japan). Before the experiments, we checked the molecular sizes of both mIgA and sIgA by electrophoresis followed by Western blotting using anti-IgA antibody. By doing so, we confirmed that the mIgA used in the study positioned at around 150 kDa and sIgA at approximately 380 kDa, values that are consistent with a previous report [15] (data not shown). The following recombinant proteins were purchased: human TGF-β1 (Pepro Tech, Rocky Hill, NJ, USA), human interleukin (IL)-1β (Tonbo Biosciences, San Diego, CA, USA) and human tumor necrosis factor (TNF)-α (R&D Systems, Minneapolis, MN, USA).
Cell culture
Normal human lung fibroblasts (NHLFs) obtained from Lonza (Walkersville, MD, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 medium (Wako Pure Chemical Industries, Osaka, Japan) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37ºC, under a 5% CO 2 atmosphere, until used for the experiments. NHLFs between passages 2 to 10 were used for the experiments.
Proliferation assay
NHLFs in DMEM/Ham's F-12 medium were seeded at 1 × 10 4 /well in 96-well plates for 24 h at 37ºC and then incubated with a stimulus and bromodeoxyuridine (BrdU) for 16 h. Cell proliferation was then assessed using a cell proliferation enzyme-linked immunosorbent assay (ELISA) kit, BrdU (colorimetric) version 16 (Roche Applied Science, Indianapolis, IN, USA). Briefly, after the culture medium was removed, the cells were fixed and DNA was denatured. The cells were then labeled with anti-BrdU-POD antibody and developed by adding the substrate solution. DNA replication, assessed based on the incorporation of BrdU, was quantified by measuring the absorbance using a scanning multi-well spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA) at 450 nm with a reference wavelength of 690 nm.
Collagen gel contraction assay
Collagen gel contraction assay was used to evaluate contraction mediated by NHLFs embedded in collagen gel matrices by measuring the gel surface area [16, 17] . First, NHLFs were mixed with Cellmatrix Type I-A (Nitta Gelatin, Osaka, Japan) in DMEM (Nitta Gelatin) to a final cell density of 3 × 10 5 cells/ml. The mixture was placed in 24-well plates in a volume of 500 µl containing 1.5 × 10 5 cells/well and allowed to gel at 37ºC for 30 min. After gelation, 500 µl of DMEM was dripped onto the gel in each well, and after 24 h the medium was replaced by fresh medium containing a stimulus. At the same time, the gel was carefully detached from the well wall using a spatula. The gel, still in the well, was then further cultured for up to 72 h at 37ºC in a 5% CO 2 atmosphere. Images of the gels at 24, 48 and 72 h were then scanned through the bottom of the plates using a scanner (Pixus MP990; Canon, Tokyo, Japan) and analyzed by measuring the gel surface area using ImageJ software (National Institutes of Health, Bethesda, MA, USA).
Western blotting
NHLFs in D-MEM/Ham's F-12 medium were seeded at 4 × 10 5 /well in 6-well plates, incubated for 24 h at 37ºC, Secretory IgA activates human lung fibroblasts and then incubated with a stimulus for 48 h. The cells were then lysed with a lysis buffer consisting of radioimmunoprecipitation assay (RIPA) buffer (Wako Pure Chemical Industries), phenylmethylsulfonyl fluoride (PMSF) as a protease inhibitor (Nacalai Tesque, Kyoto, Japan) and the production of α-smooth muscle actin (α-SMA) and collagen type 1 (Col I) by NHLFs was assessed via Western blotting. Briefly, equal amounts of protein (20 µg) from the lysates, as determined by bicinchoninic acid (BCA) assay (TaKaRa BCA Protein Assay Kit; Takara Bio Inc., Shiga, Japan), were separated on NuPAGE Bis-Tris protein gels (Thermo Fisher Scientific) and then transferred onto polyvinylidene difluoride membranes (Thermo Fisher Scientific). After blocking with WesternBreeze Blocker (Thermo Fisher Scientific) for 30 min, anti-human α-SMA antibody (1 : 1250, mouse IgG2a, clone 1A4; Sigma-Aldrich, St Louis, MO, USA), goat anti-human collagen type I antibody (1 : 2000; Southern Biotech, Birmingham, AL, USA) and anti-human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1 : 10000, mouse IgG1, clone 686613; R&D Systems) were used for detection of the proteins. The blots were developed using horseradish peroxidase (HRP)-conjugated anti-mouse or anti-goat secondary antibodies (1 : 10000) and detected using a chemiluminescent system (Amersham Imager 600; GE Healthcare, Piscataway, NJ, USA). The results were expressed as the relative ratio of the band density of the target protein to that of GAPDH using ImageQuant TL software, Version 8.1 (GE Healthcare).
Flow cytometry
To examine whether sIgA binds to NHLFs, cells were incubated with sIgA for 1 h at 4ºC. The cells were then stained with allophycocyanin (APC)-conjugated mouse antihuman IgA antibody (clone IS11-8E10; Miltenyi Biotec, Bergisch-Gladbach, Germany) or isotype control for 30 min at 4ºC. To assess expression of receptors on NHLFs, 1 × 10 5 NHLFs were incubated with a stimulus for 48 h. The cells were then incubated with 5 µg/ml of fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD71 monoclonal antibody (mAb) (IgG2aκ, clone CY1G4; BioLegend, San Diego, CA, USA) or isotype control. For detection of other receptors, cells were first labeled with anti-human CD89 mAb (mouse IgG1κ, clone A59; BioLegend), antihuman CD351 mAb (mouse IgG1κ, clone TX61; BioLegend), anti-human asialoglycoprotein receptor I (ASGPR1) mAb (mouse IgG1κ, clone 8D7; BD Pharmingen, San Jose, CA, USA) or isotype control followed by labeling with phycoerythrin (PE)-conjugated goat anti-mouse IgG (Thermo Fisher Scientific). The stained cells were analyzed using FACSVerse (BD Biosciences, Franklin Lakes, NJ, USA), and dot-plots and histograms were generated using FlowJo (Tree Star Inc., Ashland, OR, USA).
Transfection of NHLFs with siRNA targeted against CD71
NHLFs in D-MEM/Ham's F-12 medium were seeded at 0.8 × 10 5 /well in 24-well plates and incubated for 2 h at 37ºC. SiRNA against CD71 (5′rGrGUUrArCUrGrGrGrCr ArAUUUrCUrATT3′ and 5′UrArGrArArAUUrGrCr CrCrArGUrArArCrCTT3′; Sigma-Aldrich) was mixed with HiPerFect Transfection Reagent (Qiagen, Hilden, Germany) to a final concentration of 10 nM, which was then added to the cells. An equal concentration of a non-targeting, scrambled siRNA was used as a control. The cells were incubated for 24 h at 37ºC, washed with culture medium and used for the experiments.
Measurement of cytokines
NHLFs in D-MEM/Ham's F-12 medium were seeded at 1 × 10 5 /well in 24-well plates and cultured for 24 h at 37ºC. The cells were then incubated with a stimulus for 48 h, and the cell-culture supernatants were collected and stored at -20ºC until assay. For anti-IgA SC antibody (anti-SC antibody) (mouse IgG1, clone SC-05; Abcam, Cambridge, UK) treatment, sIgA and anti-SC antibody were first reacted for 1 h at 37ºC. NHLFs were then incubated with the resultant complexes for 24 h at 37ºC, followed by collection of the cell-culture supernatants. The levels of IL-6, IL-8, monocyte chemoattractant protein (MCP)-1 and granulocyte macrophage colony-stimulating factor (GM-CSF) in the cell culture supernatants were determined by cytometric bead array (CBA; BD Biosciences), according to the manufacturer's instructions.
Real-time quantitative polymerase chain reaction (RT-qPCR) analysis
NHLFs in D-MEM/Ham's F-12 medium were seeded at 1 × 10 5 /well in 24-well plates for 24 h at 37ºC. The cells were then incubated with a stimulus for the indicated times. The total RNA was extracted from the cultured cells using an RNeasy Mini kit (Qiagen), according to the manufacturer's instructions. The extracted mRNA was reversetranscribed to cDNA using a cDNA Synthesis Kit (Bio-Rad Laboratories). RT-PCR was performed using primers and Taqman probes designed by Thermo Fisher Scientific. Data were calculated by the ΔΔCt method, using β-actin as a reference. Relative quantitation (RQ) values were calculated using the following equation: RQ = 2 -ΔΔCt .
Immunohistochemistry
NHLFs in D-MEM/Ham's F-12 medium were seeded at 2×10 4 cells/well in chamber slide II (Iwaki, Tokyo, Japan) and incubated for 24 h at 37ºC. The cells were then fixed with cold acetone for 2 min and blocked with PBS containing 5% BSA and horse normal serum (Vectastain ABC
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kit; Vector Laboratories, Burlingame, CA, USA). Mouse anti-human transferrin receptor (1 : 500, mouse IgG1, clone H68.4; Thermo Fisher Scientific) and purified mouse IgG1κ isotype control (1 : 500, mouse IgG1κ; BioLegend) were used as primary antibodies. Bound primary antibodies were detected with biotin-conjugated anti-mouse IgG antibody (Vectastain ABC kit) for 30 min at 37ºC. All chamber slides were developed with peroxidase substrate kit DAB. Immunostained slides were visualized, and images were captured using a fluorescence microscope BZ-X710 (Keyence, Osaka, Japan).
Statistical analysis
Statistical differences between two groups were evaluated using the Mann-Whitney U-test. To evaluate statistical differences among three or more groups, the KruskalWallis test was performed. We used GraphPad Prism, version 7 (GraphPad Software, San Diego, CA, USA) for statistical analysis. Statistical significance was defined as a P-value of less than 0·05. Data are expressed as the mean ± standard error of mean (s.e.m.).
Results
sIgA, but not mIgA, induced production of IL-6, IL-8, MCP-1 and GM-CSF by NHLFs
First, we investigated the effect of IgA on cytokine synthesis by NHLFs using flow cytometry and RT-PCR, as lung fibroblasts produce abundant inflammatory mediators [18, 19] . As shown in Fig. 1a , production of each of IL-6, IL-8, MCP-1 and GM-CSF by NHLFs was induced dosedependently by sIgA at 100-300 μg/ml. Conversely, mIgA did not show any effect on production of those cytokines by NHLFs (Fig. 1b) . When time-course analysis was performed, production of the cytokines gradually increased from 24 h and reached a maximum at 72 h (data not shown). Expression levels of mRNA for these cytokines by NHLFs exposed to sIgA started to increase at 2 h and reached statistical significance at 4 h with sIgA at 100-300 μg/ml (Fig. 1c) , but mIgA showed no effect (Fig.  1d) . We conclude that sIgA, but not mIgA, induced production of IL-6, IL-8, MCP-1 and GM-CSF by NHLFs.
Treatment with anti-SC antibody suppressed cytokine production by NHLFs stimulated with sIgA sIgA is a J chain-containing dIgA with an SC; it is different from mIgA. CBA was used to examine whether the SC was critical to activation of NHLFs by sIgA and induction of cytokine production. Anti-SC inhibited IL-8 and MCP-1 production statistically significantly by NHLFs (Fig. 2) . IL-6 production reached statistical significance in terms of its percentage of the control MFI data (data not shown).
sIgA, but not mIgA, enhanced proliferation of NHLFs
Next, we examined effect of IgA on NHLF proliferation using an ELISA kit to measure BrdU incorporation during DNA synthesis. sIgA at 30 and 100 μg/ml significantly enhanced NHLF proliferation, and the effect was as strong as that of TGF-β1, a well-known enhancer of fibroblast proliferation [20] (Fig. 3a) . However, mIgA at 100 μg/ml did not affect NHLF proliferation (Fig. 3a) .
sIgA significantly induced collagen gel contraction by NHLFs
To further evaluate the direct effect of sIgA on NHLF function, we next performed a gel contraction assay to determine NHLFs' ability to cause contraction of collagen matrices. We found that sIgA, but not mIgA, at 100 μg/ml significantly induced collagen gel contraction by NHLFs, and the effect was as strong as, or even stronger than, that of TGF-β1 at 2·5 ng/ml ( Fig. 3b  and c) .
NHLFs produced α-SMA and Col I in response to sIgA, but not mIgA Activated lung fibroblasts are known to differentiate into myofibroblasts, for which enhanced expression of α-SMA is frequently used as a qualitative marker. Myofibroblasts play important roles, especially in tissue remodeling, wound healing and other fibrotic disorders, including IPF. Accordingly, we examined production of α-SMA by NHLFs in response to sIgA. As shown in Fig. 4a and c, incubation with sIgA enhanced synthesis of α-SMA by NHLFs at both the mRNA and protein levels. When activated myofibroblasts migrate to a damaged tissue site they synthesize extracellular matrix proteins, including collagen. As shown in Fig. 4b and d, sIgA 100 μg/ ml also induced Col I production by NHLFs at both mRNA and protein levels; however, mIgA did not influence NHLFs' production of either α-SMA or Col I (data not shown).
NHLFs bind sIgA on their cell surface and express a known IgA-receptor, CD71, on their surface
To examine whether sIgA binds directly to NHLFs, we used fluorochrome-conjugated anti-IgA antibody and flow cytometry. sIgA at 100 μg/ml showed significant binding to NHLFs (Fig. 5a and b) , while binding of mIgA was weaker (data not shown). Based on this result, we next sought to identify the receptor(s) to which sIgA bound. Others reported that more than one receptor can bind IgA [21] . Among the known IgA receptors, NHLFs 1 and granulocyte macrophage colony-stimulating factor (GM-CSF) in the NHLF culture supernatants were determined by cytometric bead array (CBA). Bars represent the mean ± standard error of the mean (s.e.m.) (n = 3 independent experiments). *P < 0·05, ***P < 0·01, ****P < 0·001 versus cells without stimulus. (c,d) NHLFs were cultured in the presence and absence of sIgA or mIgA at the indicated concentrations for 4 h. The relative expression levels of mRNA for IL-6, IL-8, MCP-1 and GM-CSF were determined by real-time polymerase chain reaction (PCR) and expressed as the mean ± s.e.m. (n = 3 independent experiments). *P < 0·05; **P < 0·01; ***P < 0·001; ****P < 0.0001 versus cells without stimulus.
S. Arakawa et al.
expressed CD71 on their cell surface ( Fig. 5c and d ) and also at the mRNA level, as assessed by RT-PCR (data not shown). We also confirmed expression of CD71 by cultured NHLFs using immunochemistry (Fig. 5e) . Interestingly, CD71 expression on NHLFs was strongly induced by incubation with two inflammatory cytokines, TNF-α and IL-1β, which are known to be involved in inflammatory disorders as well as fibroproliferative disorders [22] (Fig. 5f and g ). Three other known receptors; namely, CD89 (Fc receptor for IgA, FcαR), ASGPR and CD351 (Fc receptor for IgM and IgA, Fcα/μR), were not detected on NHLFs at either the mRNA (data not shown) or protein level (Fig. 5h) . These results suggest that sIgA binds to CD71 expressed on the cell surface of NHLFs.
sIgA affects NHLF functions, at least partly, through CD71
To elucidate the importance of CD71 expressed by NHLFs to the effects of sIgA, we examined whether siRNA knockdown of CD71 on NHLFs inhibited binding of sIgA. As shown in Fig. 6a , siRNA knock-down of CD71 was efficient at the protein level (as well as the mRNA level; data not shown), and the level of sIgA bound to NHLFs was reduced by CD71 siRNA transfection (Fig. 6b) . We also examined the effect of CD71 siRNA on production of IL-8 and MCP-1 by NHLFs stimulated with sIgA. We found that CD71 siRNA partially but significantly suppressed NHLFs' production of both of those chemokines (Fig. 6c) . These results suggest that, at least to some extent, sIgA may activate NHLFs through binding to CD71. 2 . Effect of anti-IgA secretory component antibody (anti-SC) treatment on cytokine production by normal human lung fibroblasts (NHLFs) with secretory immunoglobulin A (sIgA) stimulation. NHLFs were cultured for 24 h with sIgA at 0 and 100 µg/ml, followed by incubation with anti-SC at 0, 1 and 10 µg/ml for 1 h at room temperature. The levels of interleukin (IL)-6, IL-8 and monocyte chemoattractant protein (MCP)-1 in the NHLF culture supernatants were determined by cytometric bead array (CBA). Bars represent the mean ± standard error of the mean (s.e.m.) (n = 3 independent experiments). *P < 0·05; ***P < 0·001 versus cells without stimulus; n.s. = not significant.
Discussion
In this study we have demonstrated, by both RT-PCR and CBA, that sIgA, but not mIgA, induced IL-6, IL-8, MCP-1 and GM-CSF production by NHLFs. sIgA also enhanced proliferation of NHLFs as assessed by cellular incorporation of BrdU and collagen gel contraction, both at levels comparable to with TGF-β1. We should note that because sIgA is much larger in size than TGF-β1, its potency on a molar basis is inferior to that of TGF-β1. Nevertheless, as the biological concentration of sIgA is much higher than that of TGF-β1, the potency we observed in our experiments is biologically possible. In addition, Western blotting showed that Col I, a component of the extracellular matrix, and α-SMA, a commonly used marker for myofibroblast differentiation, were also up-regulated by sIgA. Finally, we demonstrated that sIgA binds to NHLFs, presumably to CD71, known as a transferrin receptor, and that knock-down of CD71 at least partly inhibited cytokine production by NHLFs.
The protective role of sIgA has long been of interest, whereas other activities of sIgA have not been focused upon, at least in the pathogenesis of lung diseases. For example, patients with selective IgA deficiency, the most common primary immunodeficiency, often develop recurrent sinopulmonary infections and allergic as well as autoimmune diseases [23] , suggestive of a definite role for IgA in protection against pathogens and antigens. Conversely, some reports indicated pathophysiological roles for IgA, especially in other organs such as the kidney, liver and intestinal tract [24] [25] [26] [27] , suggesting that it may have effects on various human diseases. Those reports led us to hypothesize that IgA may have effects on other human diseases. In order to test that hypothesis we (a) NHLFs were cultured with sIgA or monomeric IgA (mIgA) at 100 µg/ml or transforming growth factor (TGF)-β1 at 10 ng/ml, with bromodeoxyuridine (BrdU) for 16 h, and BrdU incorporation was analyzed using a cell proliferation enzyme-linked immunosorbent assay (ELISA) kit. Bars represent the mean ± standard error of the mean (s.e.m.) (n = 3 independent experiments). *P < 0·05; ***P < 0·001; ****P < 0·0001 versus cells without stimulus. conducted the present study, which generated evidence of a new pathological activity for sIgA. That is, whereas biological levels of sIgA of approximately 10-200 μg/ml in the human epithelial lining fluid [28] induced activation of lung fibroblasts that may be beneficial in tissue repair and regeneration, at the same time such activation may be detrimental in fibroproliferative disorders such as IPF.
Several cytokines are known to act in combination to induce epithelial damage and persistent inflammation, resulting in tissue fibrosis in fibrosing disorders, including IPF, in the lung. For example, IL-6 plays an important role in induction of leukocyte infiltration during acute inflammation that may lead to fibrosis [29] [30] [31] [32] . Similarly, IL-8 exhibits a wide range of proinflammatory activities, especially in neutrophil-mediated acute inflammation. IL-8 Fig. 4 . Secretory immunoglobulin A (sIgA) enhances production of α-smooth muscle actin (SMA) and collagen type 1 (Col I) by normal human lung fibroblasts (NHLFs). (a,b) NHLFs were cultured in the presence and absence of sIgA at the indicated concentrations for 4 h (α-SMA) and 24 h (Col I). The relative expression levels of mRNA for α-SMA and Col I were determined by real-time polymerase chain reaction (PCR) and expressed as the mean ± standard error of the mean (s.e.m.) (n = 5 independent experiments). *P < 0·05; **P < 0·01 versus cells without stimulus. (c,d) NHLFs were cultured in the presence and absence of sIgA at 100 µg/ml for 48 h, and the cell lysates were collected to quantitate α-SMA (c) and Col I (d) by Western blot analysis. Three independent samples from separate experiments were applied onto each gel for electrophoresis, followed by Western blot analysis. The expression of each was normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed as the mean ± s.e.m. (n = 3, 11 independent experiments). *P < 0·05; **P < 0·01. Secretory IgA activates human lung fibroblasts and MCP-1 have been well documented to act as chemotactic factors for neutrophils, monocytes, mast cells, fibrocytes and T helper type 17 (Th17) cells in the lung [33] [34] [35] [36] [37] . Accumulation of neutrophils in the alveolitis of IPF is a characteristic feature of that disease [38] , and high levels of neutrophil-origin elastase have been observed in the bronchoalveolar lavage fluid (BALF) of IPF patients [39] . Taken together, sIgA may enhance both inflammation and fibrosis in the lung by inducing IL-6, IL-8 and MCP-1 production by NHLFs. However, the roles of GM-CSF in tissue repair and fibrosis remain controversial. GM-CSF deficiency reportedly resulted in enhanced fibrogenesis in a bleomycininduced pulmonary fibrosis model in mice, suggesting a protective role for GM-CSF [40] . Conversely, GM-CSF stimulated keratinocyte proliferation [41] , and over-expression of GM-CSF in the lung resulted in lung fibrosis and inflammation by recruiting macrophages and eosinophils into the lung, indicating a pathogenic role for GM-CSF in lung fibrosis [42] . The roles of GM-CSF may differ in humans compared to mice, and also may depend on the inflammatory status of each individual. However, as GM-CSF is known to recruit granulocytes and macrophages to sites of inflammation [43] , sIgA-induced GM-CSF production by NHLFs may accelerate the pathogenesis of IPF.
Fibroblasts in IPF, i.e. activated fibroblasts and myofibroblasts, are identified by high expression levels of α-SMA and have distinct properties: high ability to proliferate and to produce extracellular matrix, proteases and fibrogenic cytokines and contractile activity [44, 45] . Therefore, differentiation of fibroblasts to myofibroblasts is thought to be the key step in the development of tissue fibrosis. Our present study demonstrated that sIgA enhanced expression of α-SMA by NHLFs, indicating that sIgA might induce myofibroblast differentiation. Our data further support the importance of sIgA for NHLF activation and differentiation by showing that it induced proliferation, collagen gel contraction and Col I production by NHLFs. In particular, the effects of sIgA on proliferation and collagen gel contraction are interesting because they were comparable to those of TGF-β1, one of the most potent fibrogenic cytokines. Activation of fibroblasts is essential for tissue repair and regeneration as well as for maintenance of biological homeostasis, and here we may have identified another protective role of sIgA. Conversely, tissue fibrosis is a critical pathogenic step in various lung diseases, including IPF, pulmonary hypertension [46] , asthma [47] and chronic obstructive pulmonary disease (COPD) [48] . Among those diseases, IPF is a chronic, progressive lung disease with a poor prognosis, characterized by fibroblast proliferation and extracellular matrix deposition. Accumulating evidence shows that IPF results from an excessive wound-healing process that leads to aberrant fibrosis in response to alveolar epithelial injury [13] . The main steps in the pathogenesis of IPF may be migration, proliferation and activation of lung fibroblasts and their differentiation into myofibroblasts, induced mainly by TGF-β [49] . In the present study, we showed that sIgA is another potent inducer of fibroblast activation. Because the airway surface as well as the surfaces of the intestines and urogenital tract are always anatomically exposed to the external environment, the function of sIgA observed in the present study may have developed to protect against tissue damage caused by invading pathogens and antigens.
Under normal conditions, lung fibroblasts are separated from airway mucus by an epithelial cell layer having firm tight-junctions [50] . However, in the initiation of lung fibrosis in IPF, deprivation of alveolar epithelial cells with basement membrane denudation is reported to occur, and the damaged area often overlies fibroblastic foci [51, 52] . We confirmed that fibroblastic foci in the IPF lung had sites where a stretch of epithelial cells had collapsed -as assessed by absence of cells stained by anti-cytokeratin antibody -and was replaced by cells positively stained by anti-vimentin antibody (Supporting information, Fig. S1 ). Therefore, under certain conditions such as IPF, sIgA in airway mucus may make contact with lung fibroblasts. In addition, although the origin of accumulated fibroblasts in IPF has not been fully determined, epithelial-mesenchymal transition (EMT) was suggested to be one possible mechanism [53] . In EMT, airway epithelial cells located adjacent to airway lumen acquire mesenchymal features [54] . Epithelial cells that had undergone EMT and acquired characteristics similar to those of mesenchymal cells may respond to sIgA, in the same manner as the NHLFs we used in our experiments. Especially under conditions with increased levels of IgA, such as when a respiratory infection co-exists, lung fibroblasts may come into direct contact with sIgA in the airway mucus, resulting in exacerbated airway inflammation and fibrosis [4, 55] .
The effects of sIgA on NHLFs were sIgA-specific, as mIgA showed no effects. The molecular importance of the SC and the different roles of mIgA and sIgA have been reported [56, 57] . The SC may be the crucial molecule in the process of sIgA's activation of NHLFs in the present setting. Indeed, we found that anti-SC antibody treatment significantly inhibited cytokine production by NHLFs (Fig. 2) . However, it must be noted that a serum IgA level in which the majority exists in the form of mIgA was reported to be a prognostic marker for IPF [10] . Although we did not detect any pathogenic role or mIgA on activation of NHLFs, the level of mIgA may be linked to the level of sIgA because both mIgA and dIgA, a component of sIgA, are produced by plasma cells. Moreover, sIgA is especially present in the blood in certain conditions such as inflammatory diseases [58, 59] .
We also found that CD71, a transferrin receptor, was at least partially responsible for the effects of sIgA on NHLFs. However, it does not seem to be the only receptor involved, as its knock-down did not completely eliminate sIgA's binding to NHLFs or its effects on cytokine production by NHLFs. Also, because CD71 is a critical receptor for human life, as it is required for iron import into cells [60] and is essential for cell maintenance, targeting CD71 to abrogate the effects of sIgA on certain fibrogenic diseases does not seem realistic. Further investigation of possible involved receptors and the intracellular signaling pathway is warranted.
In summary, we have demonstrated that sIgA, but not mIgA, induced various responses of NHLFs: IL-6, IL-8, MCP-1 and GM-CSF production, proliferation and collagen gel contraction. sIgA was also able to enhance Col I and α-SMA production by NHLFs, and we showed that it binds to NHLFs, at least partly via CD71. Overall, our experiments demonstrate the important role of sIgA in activation of fibroblasts which may be due partially to its binding to CD71. However, additional -as yet undetermined -receptors may also be involved in the pathway and need to be elucidated.
